CAMP4 Therapeutics grants inducement stock options to new employee

1 min read Updated on 18 Jul 2026, 01:48 AM

Reviewed by

Ashish TScanX News Team

AI Summary

CAMP4 Therapeutics Corporation granted non-qualified stock options for 8,000 shares to a new employee under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.21 per share, a ten-year term, and vest over four years. The grant aligns with the company’s 2026 Inducement Plan to incentivize new talent.

*this image is generated using AI for illustrative purposes only.

CAMP4 Therapeutics Corporation granted non-qualified stock options to purchase 8,000 shares of its common stock to a newly hired employee as an inducement material to their entry into employment. The grant, approved by the Compensation Committee of the company’s Board of Directors on July 15, 2026, was made in accordance with Nasdaq Listing Rule 5635(c)(4). This move aims to attract talent by offering equity incentives aligned with the company’s long-term performance.

The Inducement Grant carries a ten-year term and an exercise price of $4.21 per share, matching the closing price of CAMP4’s common stock on the Grant Date. Vesting occurs over a four-year period, with 25% of the shares vesting on the first anniversary of the employee’s employment start date. The remaining 75% vests in 36 equal monthly installments, contingent upon the employee’s continued service with CAMP4 through the applicable vesting dates.

Grant Details

Parameter	Details
Grant Date	July 15, 2026
Shares Granted	8,000
Exercise Price per Share	$4.21
Term	10 years
Vesting Schedule	25% at one year; remainder in 36 equal monthly installments
Governing Plan	2026 Inducement Plan

The grant is subject to the terms and conditions of the company’s 2026 Inducement Plan and the applicable non-qualified stock option agreement. CAMP4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-targeting therapeutics designed to upregulate gene expression for treating genetic diseases.

How might this hiring strategy impact CAMP4's ability to attract top talent in the competitive biopharmaceutical sector?

What are the potential implications of the 2026 Inducement Plan on future employee retention and company performance?

Could this grant signal a broader trend of increased equity-based compensation in the biotech industry?

Read Next Article

CAMP4 Therapeutics grants inducement options to new hires

1 min read Updated on 20 Jun 2026, 01:45 AM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

AI Summary

CAMP4 Therapeutics Corporation granted non-qualified stock options for 39,000 shares to three new employees under Nasdaq Listing Rule 5635(c)(4). The options, priced at $3.96 per share, vest over four years with a ten-year term.

*this image is generated using AI for illustrative purposes only.

CAMP4 Therapeutics Corporation granted non-qualified stock options to purchase an aggregate of 39,000 shares of its common stock to three newly hired employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors on June 15, 2026, as an inducement material to the employees' entry into employment. The awards were issued in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grants each have a ten-year term and an exercise price of $3.96 per share, which equals the closing price of CAMP4’s common stock on the Grant Date. The options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment. The remainder will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates.

Grant Details

Feature	Details
Total Shares Granted	39,000
Exercise Price	$3.96 per share
Grant Date	June 15, 2026
Term	10 years
Vesting Schedule	4 years (25% at 1 year, remainder monthly)

Each Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable non-qualified stock option agreement. CAMP4 is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression.

How will the addition of these three new employees impact CAMP4's clinical development timelines over the next year?

Does this hiring signal a strategic shift in CAMP4's focus towards specific therapeutic areas or RNA targets?

What are the implications of the $3.96 exercise price on employee retention if the stock price fluctuates significantly?